Reports Q4 revenue $176.8M, consensus $172.7M. “As many in the industry are choosing to capitulate, ATEC, the largest pure-play spine company, remains focused on revolutionizing spine care,” asserted Pat Miles, Chairman and Chief Executive Officer. “The coming years will be our best yet. We are expanding our influence in deformity through EOS-integrated, procedure-specific technologies. We are thrilled to have performed our first surgeries in Japan, the world’s second-largest spine market. The durable revenue growth that we are driving, combined with sharpened operational discipline, position us for self-funded growth in 2025 and beyond.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- ATEC Earnings this Week: How Will it Perform?
- Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street
- Alphatec price target raised to $21 from $20 at Barclays
- Alphatec price target raised to $19 from $16 at Jefferies
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz